WAYNE, Pa.--(EON: Enhanced Online News)--Life Sciences Pennsylvania, the statewide trade association representing Pennsylvania’s life science industry, announced today the three finalists for its 2016 Patient Impact Award. The 2016 award finalists are The Emily Whitehead Foundation, Jefferson Health, and Merck & Co., Inc. The winner will be announced at Life Sciences Pennsylvania’s Annual Dinner March 9, 2017 at the Pennsylvania Convention Center in Philadelphia.
Life Sciences Pennsylvania’s Patient Impact Award recognizes a company or organization that has made a significant contribution to the quality of healthcare or length of life of patients in 2016.
“The finalists for the 2016 Patient Impact Award demonstrate the diversity of efforts and steadfast dedication to life-changing and live-saving medical treatments,” said Christopher P. Molineaux, President & CEO of Life Sciences Pennsylvania. “Any one of these organizations would be a deserving winner.”
The Emily Whitehead Foundation
The Emily Whitehead Foundation was created to help provide researchers the funding they need to find less toxic treatments for pediatric cancer. The Foundation’s focus is on funding the most promising research such as the T-cell therapy that Emily Whitehead received and other immunotherapies. The Foundation also continues to share Emily’s story to promote awareness and inspire others to take action and make a difference.
Through the work of Judd Hollander, MD, and Steven K. Klasko, MD, MBA, the visionaries behind Jefferson Health’s “JeffConnect,” patients are now able to see a Jefferson doctor at any time, anywhere – using a phone, tablet or computer – offering ease of service, quality of care and speed at which they can speak to a medical professional. Patients save time and are able to receive on-demand care through JeffConnect.
Merck & Co., Inc.
Merck & Co., Inc. has been nominated for its development and continued evolution of KEYTRUDA, one of the industry’s first anti-PD-1 therapies to treat various types of cancer. Since FDA approval of this product, Merck has undertaken a robust program to treat other tumor types and expand its coverage in the treatment to become the first line therapy for metastatic NSCLC whose tumors have high PD-L1 expression.
About the Life Sciences Pennsylvania Annual Dinner
Life Sciences Pennsylvania's Annual Dinner is the region's most anticipated and highly attended event for top life science professionals and business executives, hosting more than 1,000 guests each year since 2011. For more information on the Annual Dinner and to purchase tickets, please visit www.lifesciencespa.org.
About Life Sciences Pennsylvania
Life Sciences Pennsylvania (formerly Pennsylvania Bio) was founded in 1989 by two Penn State researchers. Today it has grown to represent the entire life sciences industry – biotech, medical device, diagnostic, and pharmaceutical companies; investment organizations; research institutions; digital health companies and the myriad service industries that support the life sciences in Pennsylvania. Life Sciences Pennsylvania’s mission is to ensure Pennsylvania is the United States hub for the life sciences by creating a business and public policy environment which fosters life sciences growth and success. More information is available at http://www.lifesciencespa.org.